Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumors

13 Feb 2018

Abstract excerpt

// Bruce W. Konicek 1 , Andrew R. Capen 1 , Kelly M. Credille 1 , Philip J. Ebert 1 , Beverly L. Falcon 1 , Gary L. Heady 1 , Bharvin K.R. Patel 1 , Victoria L. Peek 1 , Jennifer R. Stephens 1 , Julie A. Stewart 1 , Stephanie L. Stout 1 , David E. Timm 1 , Suzane L. Um 1 , Melinda D. Willard 1 , Isabella H. Wulur 1 , Yi Zeng 1 , Yong Wang 1 , Richard A. Walgren 1 and Sau-Chi Betty Yan 1 1 Lilly Research...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Mechanisms and Therapy
Share to Chronic Myeloid Leukemia Treatments
Share to Phagocytosis and Immune Regulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29568395
DOI: 10.18632/oncotarget.24488

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Merestinib (LY2801653) inhibits neurotrophic receptor kinase (NTRK) and suppresses growth of NTRK fusion bearing tumorsPMID 29568395Read ↗

Emerging Targeted Therapy for Tumors with NTRK Fusion Proteins.Semantic proximity Read ↗

Belgian expert consensus for tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinibSemantic proximity Read ↗

Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancerSemantic proximity Read ↗

Evaluating larotrectinib for the treatment of advanced solid tumors harboring an NTRK gene fusionSemantic proximity Read ↗

NTRK gene fusions as novel targets of cancer therapy across multiple tumour typesSemantic proximity Read ↗

TRK Inhibition: A New Tumor-Agnostic Treatment StrategySemantic proximity Read ↗

A review of NTRK fusions in cancerSemantic proximity Read ↗

Tropomyosin Receptor Kinase Inhibitors for the Treatment of TRK Fusion CancerSemantic proximity Read ↗

Antitumor activity of larotrectinib in tumors harboring NTRK gene fusions: a short review on the current evidenceSemantic proximity Read ↗

TRK inhibitor activity and resistance in TRK fusion-positive cancers in adults.Semantic proximity Read ↗

Safety of current treatment options for NTRK fusion-positive cancersSemantic proximity Read ↗

Discovery and characterization of targetable NTRK point mutations in hematologic neoplasmsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.